Cancer associated thrombosis: risk factors and outcomes

• Patients with cancer are at increased risk of venous and arterial thrombosis.
• and have a higher prevalence of venous thrombosis at unusual sites including upper extremity, splanchnic or cerebral veins.
• The risk is driven and modified by general risk factors such as surgery, hospitalisation, infection and genetic coagulation disorders, by cancer-specific factors including type, histology, and stage of the malignancy, cancer treatment and certain biomarkers.
• A venous thrombotic event in a cancer patient has serious consequences as the risk of recurrent thrombosis, the risk of bleeding during anticoagulation and hospitalisation rates are increased, and survival time is decreased.

ABSTRACTDeep vein thrombosis of the leg and pulmonary embolism are frequent diseases and cancer is one of their most important risk factors. Patients with cancer also have a higher prevalence of venous thrombosis located in other parts than in the legs and/or in unusual sites including upper extremity, splanchnic or cerebral veins. Cancer also affects the risk of arterial thrombotic events particularly in patients with myeloproliferative neoplasms and in vascular endothelial growth factor receptor inhibitor recipients. Several risk factors need to interact to trigger thrombosis. In addition to common risk factors such as surgery, hospitalisation, infection and genetic coagulation disorders, the thrombotic risk is also driven and modified by cancer-specific factors including type, histology, and stage of the malignancy, cancer treatment and certain biomarkers. A venous thrombotic event in a cancer patient has serious consequences as the risk of recurrent thrombosis, the risk of bleeding during anticoagulation and hospitalisation rates are all increased. Survival of cancer patients with thrombosis is worse compared to that of cancer patients without thrombosis, and thrombosis is a leading direct cause of death in cancer patients.